A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.
Posted Date: Apr 5, 2018
- Investigator: John Morris
- Specialties: Gastroenterology, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
- Type of Study: Drug
to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given before and after surgery. The addition of these chemotherapy drugs before surgery is a new approach that is being tested in this study. This new approach could prevent your cancer from returning, but it could also cause side-effects. This study will allow the researchers to know if it is a good idea to treat pancreatic cancer with chemotherapy drugs before surgery
To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.
Pancreatic, S1505, Resectable, Cancer, Gastrointestinal
For More Information:
Uc Cancer Institute